Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and workforce development
2026 · 2nd Quarter (Apr 1 - June 30)
PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION
Filed by PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 14, 2026
- Income
- Not reported
- Expenses
- $50,000.00
- Filing UUID
- 8a2f5a86-68e3-487f-a245-4adf0c325a64
- Termination date
- Not reported
Expense method: C
Literal source text
Lobbying issues and bill citations
Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and workforce development
Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and workforce development
Discussed issues related to biopharma supply chain tariff implementation, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, and workforce development
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.